- Home
- Equipment
- usa massachusetts
- ovarian cancer
Show results for
Refine by
Ovarian Cancer Equipment Supplied In Usa Massachusetts
7 equipment items found
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. UpRi is being studied in UPLIFT, a single-arm ...
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
Our first ex vivo development candidate seeks to treat acute myeloid leukemia (AML) by engineering autologous T cell receptors (TCR) directed towards the Wilms’ Tumor 1 (WT1) antigen, an over-expressed protein that is often associated with AML and other cancers. We have nominated NTLA-5001 as our initial development candidate for AML and expect to enter the clinic in 2021. ...
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
AV-203 (CAN017) is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
The Dolaflexin platform was designed to increase the efficacy, safety, and tolerability of ADCs. This platform overcomes the limitations of traditional ADCs in which drugs are directly conjugated to antibodies. Dolaflexin utilizes our proprietary Fleximer polymer, a biodegradable, highly biocompatible, water-soluble polymer able to carry multiple drug molecules. Instead of direct conjugation to ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Ombipepimut-S Emulsion (DSP-7888) is an investigational immunotherapeutic cancer vaccine containing 2 peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTLs) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic malignancies and solid tumors.1,2 Researchers have identified that adding helper T-cell–inducing peptides improved ...
Manufactured by:LifeSpan BioSciences, Inc based inShirley, MASSACHUSETTS (USA)
LTB4R2 is a low-affinity receptor for leukotrienes including leukotriene B4. It mediates the chemotaxis of granulocytes and macrophages. The response is mediated via G-proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of affinities for the leukotrienes is LTB4 > 12-epi-LTB4 > LTB5 > LTB3. LTB4R2 has been found to be overexpressed in esophageal ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Poor Solubility and Associated Formulation and Bioavailability Difficulties. Although paclitaxel is an effective anticancer drug, its solubility is low (~ 0.4 µg/mL), which limits its medical utility to intravenous applications. Docetaxel (Taxotere®) was developed as a paclitaxel derivative having improved water solubility; its solubility, however, is only ~ 14 µg/mL. Several ...